Safety and PK of GC4711 vs GC4419 in Healthy Volunteers

Phase 1, randomised, double-blind trial of rucosopasem manganese in pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Galera Therapeutics, Inc. Primary endpoints: Frequency, duration, and severity of adverse events up to 6 days and Incidence of clinically significant laboratory abnormalities up to 6 days. Started Sep 2017; status: completed.